Three Not A Magic Number For Mayne With Another NuvaRing CRL

Follows CRLs Handed Out By US FDA To Australian Firm In 2018 And 2020

Australia’s Mayne Pharma has announced another complete response letter for its proposed generic version of Organon’s NuvaRing (etonogestrel/ethinylestradiol) contraceptive device, marking a trio of setbacks for the ANDA product.

Three Fingers Hand Sky
Mayne has received a third CRL over its NuvaRing rival • Source: Alamy

Mayne Pharma’s proposed generic version of Organon’s NuvaRing (etonogestrel/ethinylestradiol) contraceptive device in the US is proving to be something of an albatross for the company, with the US Food and Drug Administration once again issuing a complete response letter detailing that it cannot approve the firm’s application in its current form.

The Australian firm said it was “working closely with its development partner, Mithra, and the FDA to address the questions raised in the CRL,” without providing any further specific detail....

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Generics

After Dasatinib Apotex Debuts US Tasigna Competition

 
• By 

Canada’s Apotex is continuing to spearhead generic competition in the tyrosine kinase inhibitor (TKI) space for chronic myelogenous leukemia, with the launch of the first generic version of Novartis’ Tasigna (nilotinib) blockbuster.

Regulatory Recap: ICH To Determine The Future Of Biosimilar Comparative Efficacy Studies

 

Generics Bulletin reviews global regulatory developments across the world.

Advanz Allies With Pharmathen On Long-Acting Injectable

 
• By 

Advanz Pharma has announced details of a fresh alliance on long-acting injectables with Pharmathen.

ANI Raises Generics Guidance As Exclusive Prucalopride Drives Growth

 
• By 

ANI Pharmaceuticals says it has delivered an “exceptionally strong first quarter,” with total sales reaching over $197m, amid plans to kick off a Phase IV clinical trial for Cortrophin Gel for acute gouty arthritis later this year.

More from Products

Hikma Gears Up To Enter US Biosimilars Market With Ustekinumab Nod

 
• By 

Hikma is set to make its first launch into the competitive US biosimilars market after its Bio-Thera-partnered Stelara rival, Starjemza, was approved by the FDA.

Regulatory Recap: ICH To Determine The Future Of Biosimilar Comparative Efficacy Studies

 

Generics Bulletin reviews global regulatory developments across the world.

Advanz Allies With Pharmathen On Long-Acting Injectable

 
• By 

Advanz Pharma has announced details of a fresh alliance on long-acting injectables with Pharmathen.